View Older Stories View More Recent Stories

Jul 12, 2023 04:31PM Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma
Jun 20, 2023 07:30AM BridgeBio Pharma Inc. (BBIO) Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib
Jun 20, 2023 07:30AM BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
Jun 13, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Jun 8, 2023 07:30AM BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual
May 22, 2023 07:30AM BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Mee
May 15, 2023 07:30AM BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 11, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 4, 2023 07:30AM BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
Apr 27, 2023 07:30AM BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
Apr 27, 2023 07:30AM BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
Apr 11, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 11, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 7, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 7, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 23, 2023 07:30AM BridgeBio Pharma (BBIO) Doses First Lung Cancer Patient Dosed in Phase 1 Trial for BBP-398
Mar 23, 2023 07:30AM BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Mar 23, 2023 07:30AM BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Mar 21, 2023 07:30AM BridgeBio Pharma (BBIO) Reports Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan
Mar 21, 2023 07:30AM BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
Mar 21, 2023 07:30AM BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
Mar 17, 2023 07:30AM BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
Mar 17, 2023 07:30AM BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
Mar 6, 2023 07:00AM BridgeBio Pharma Inc. (BBIO) Reports Positive Phase 2 Cohort 5 Results of Infigratinib
Mar 6, 2023 07:00AM BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Even
Mar 6, 2023 07:00AM BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Even
Mar 3, 2023 07:30AM BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
Mar 3, 2023 07:30AM BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
Feb 23, 2023 07:30AM BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
Feb 23, 2023 07:30AM BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
Feb 17, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Feb 17, 2023 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Feb 13, 2023 07:30AM BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
Feb 13, 2023 07:30AM BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
Feb 8, 2023 07:30AM BridgeBio Pharma to Participate in February and March Investor Events
Feb 8, 2023 07:30AM BridgeBio Pharma to Participate in February and March Investor Events
Jan 4, 2023 07:30AM BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
Jan 4, 2023 07:30AM BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
Dec 22, 2022 07:31AM BridgeBio Pharma Inc. (BBIO) initiates phase 3 randomized trial of encaleret in ADH1
Dec 22, 2022 07:30AM BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
Dec 22, 2022 07:30AM BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
Nov 9, 2022 07:30AM BridgeBio Pharma to Participate in November Investor Events
Nov 9, 2022 07:30AM BridgeBio Pharma to Participate in November Investor Events
Nov 3, 2022 07:30AM BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
Nov 3, 2022 07:30AM BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
Oct 17, 2022 12:30PM BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symp
Oct 17, 2022 12:30PM BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symp
Oct 14, 2022 07:30AM BridgeBio Pharma (BBIO) Reports 12-month Results from Phase 2 Study of BBP-418
Oct 14, 2022 07:30AM BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
Oct 14, 2022 07:30AM BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
View More Recent Stories View Older Stories